Browse Articles

A dual role of fibroblast–epithelial crosstalk in acute and chronic lung injury

Low-mass zinc pools in Escherichia coli: Micromolar concentrations, diverse compositions, and Zn-glutathione dominating under Zn-replete conditions

Polyamines stimulate the protein synthesis of the translation initiation factor eIF5A2, participating in mRNA decoding, distinct from eIF5A1

Antibacterial ADP-ribosyl cyclase toxins inhibit bacterial growth by rapidly depleting NAD(P)+

Secretory autophagy mediates lysosomal and autophagic degradation for α-synuclein proteostasis

Targeting HIF-P4H-2 in APP/PS1 Alzheimer’s mouse model improves glucose metabolism, reduces dystrophic neuritis, and maintains exploratory activity

Active site determinants of yeast Pah1 phosphatidate phosphatase activity and cellular functions

Dimerization of Cdc13 is essential for dynamic DNA exchange on telomeric DNA

The ability of SAMHD1-deficient monocytes to trigger the Type I IFN response depends on cGAS and mitochondrial DNA

Modulation of the PTPRS proteoglycan switch by antibodies binding to the membrane-proximal fibronectin-type III domain

Dynamic regulation of Sec24C by phosphorylation and O-GlcNAcylation during cell cycle progression

Restricted human CD45 isoglycoforms serve as functional E-selectin ligands and delineate hematopoietic maturity

Structural and functional characterization of CREB-binding protein (CREBBP) as a histone propionyltransferase

Synergy between RNA editing and alternative splicing modulates the biological properties of the voltage-gated calcium channel CaV1.3

Second-line tarlatamab improves OS in SCLC

Hsp110 nucleotide exchange factors may amplify Hsp70-disaggregation by enhanced entropic pulling

The next generation of immunotherapies for lung cancers

Exploring the regulatory mechanism of CCNA2 in colorectal cancer: Insights from multiomics and experimental analysis

The role of chromatin in retroviral preintegration complex function

Medical costs for patients with rheumatoid arthritis who have comorbid diabetes mellitus

Objectives To evaluate medical costs and resource use in patients with rheumatoid arthritis (RA) with and without diabetes mellitus (DM). Methods Data were obtained from the Japan Medical Data Center (JMDC) claims database. The baseline period comprised 6 months before the index date (first prescription date post-RA diagnosis) while the 12-month duration post-index date was the follow-up period. Patients with RA and DM prescribed an antidiabetic drug in the baseline period constituted the DM group, while patients with RA without DM or an antidiabetic prescription in the baseline and follow-up periods belonged to the non-DM group. Patients were matched by sex, age, Charlson Comorbidity Index (CCI), months from the first RA codes, and medications. The primary endpoint was total medical costs per patient in the follow-up period. The secondary endpoints were costs for drugs, treatments, and materials, their sub-categories, and proportions of patients using the sub-categories. Results One hundred and sixty-one DM group patients and 2,974 non-DM group patients were eligible for inclusion, and 109 patients were matched from each group. The median values of age and CCI were 59 years and 2.0 in both groups. After excluding DM-specific costs, both total medical costs and drug costs were significantly higher in the DM group compared with the non-DM group (total medical costs: DM/ non-DM: 5,163 USD/ 3,782 USD, P < 0.05; drug costs: DM/ non-DM: 2,242 USD/ 1,066 USD, P < 0.05) because of a higher proportion of biological disease-modifying antirheumatic drug (DMARD) users in the DM group (DM/ non-DM: 14.7%/ 5.5%). Treatment costs and material costs did not differ between the two groups. Conclusions Medical costs for RA were higher in the DM group than in the non-DM group because of a higher proportion of biological DMARD users.